Arteriovenous fistula (AVF) is an irregular connection between an artery and a vein that bypasses capillaries. Normal blood flow is disturbed in the condition, which in turn lowers peripheral resistance and raises cardiac output. AVFs can be congenital, a consequence of trauma or genetic disorders, or surgically produced for dialysis access in patients with kidney failure. The symptoms include visible purplish veins, edema, exhaustion, and lowered blood pressure. Untreated large AVFs may result in blood clots or extended cardiac strain, which can lead to heart failure. Imaging and physical examinations are used to make the diagnosis, which looks for noises that resemble machinery. Risk factors include immune disorders and viral infections. The arteriovenous fistula pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the arteriovenous fistula pipeline analysis include Humacyte, Inc., Vascular Therapies, Inc., and Medtronic among others.
Leading drugs currently in the pipeline include sirolimus, human acellular vessel (HAV) and others.
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Arteriovenous Fistula Pipeline Analysis Report by Expert Market Research gives comprehensive insights into arteriovenous fistula therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for arteriovenous fistula therapeutics. The arteriovenous fistula report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The arteriovenous fistula pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with arteriovenous fistula treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to arteriovenous fistula.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
An arteriovenous fistula (AVF) disrupts the hemodynamics, causing turbulent flow and endothelial injury when high-pressure arterial blood is forced into low-pressure veins. Inflammation and neointimal hyperplasia (vascular wall thickening) are brought on by chronic endothelial activation, which frequently results in stenosis and delayed AVF maturation.
Abnormal connections between arteries and veins that avoid capillaries are known as arteriovenous fistulas (AVFs). They may be formed surgically for dialysis access, develop organically, or be the consequence of trauma. AVFs cause high-pressure arterial blood to enter veins, disrupting normal blood flow. This can result in issues including blood clots or heart strain, as well as vascular dilatation and swelling. Depending on size, location, and severity, treatment options include stent implantation, compression therapy, catheter-based embolization, monitoring, and surgical repair.
Globally, the prevalence of arteriovenous fistulas (AVFs) varies depending on clinical and demographic parameters. In patients with end-stage kidney disease, AVFs are frequently made for hemodialysis. Fistula development is somewhat more common in men. Research indicates that AVFs are primarily formed in the brachiobasilic and brachiocephalic regions of the upper extremities. Regional differences in practice patterns and success rates are influenced by factors such as diabetes, hypertension, and vascular health, which also affect prevalence and outcomes.
This section of the report covers the analysis of arteriovenous fistula drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total arteriovenous fistula clinical trials. All ongoing clinical trials in the arteriovenous fistula pipeline are currently in Phase III, focusing on efficacy, safety, and long-term outcomes.
The drug molecule categories covered under the arteriovenous fistula pipeline analysis include monoclonal antibody, peptides, small molecule and gene therapy. The arteriovenous fistula report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for arteriovenous fistula.
The EMR report for the arteriovenous fistula pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in arteriovenous fistula clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for arteriovenous fistula. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of arteriovenous fistula drug candidates.
Vascular Therapies has developed Sirolimus, a proprietary sirolimus formulation aimed at enhancing arteriovenous fistula (AVF) maturation in hemodialysis patients. The drug is being evaluated in the ACCESS 2 trial, a Phase III multinational study, that enrolled 136 patients across 17 centers in the United States and United Kingdom. Topline results, focusing on six-month fistula maturation, are anticipated in Q2 2025.
The human acellular vessel (HAV) is a bioengineered, commercially available vascular conduit that may be implanted without immunosuppression, created by Humacyte. The FDA has designated the HAV as a regenerative medicine advanced therapy (RMAT) for immediate arterial repair after vascular injuries to the extremities. It is currently undergoing Phase 3 clinical studies and has demonstrated successful real-world uses in Ukraine, with higher patency rates and fewer infection risks than synthetic grafts.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Arteriovenous Fistula Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for arteriovenous fistula. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into arteriovenous fistula collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share